TransMedics Group (NASDAQ:TMDX) Given Buy Rating at Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note published on Tuesday,Benzinga reports. The brokerage currently has a $104.00 price objective on the stock.

Several other analysts also recently issued reports on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Robert W. Baird reduced their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Piper Sandler reduced their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Finally, TD Cowen reduced their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Price Performance

NASDAQ TMDX opened at $67.65 on Tuesday. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a fifty day simple moving average of $68.55 and a 200 day simple moving average of $95.67. The company has a market cap of $2.28 billion, a P/E ratio of 71.97 and a beta of 2.12. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $177.37.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in TMDX. Atlas Capital Advisors Inc. bought a new position in shares of TransMedics Group during the 4th quarter worth about $31,000. Hager Investment Management Services LLC acquired a new stake in shares of TransMedics Group during the 4th quarter worth about $33,000. Sachetta LLC acquired a new stake in shares of TransMedics Group during the 4th quarter worth about $40,000. AlphaQuest LLC acquired a new stake in shares of TransMedics Group during the 4th quarter worth about $52,000. Finally, Quarry LP increased its position in shares of TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.